Nevro share price today

(NVRO)

Nevro share price is $4.05 & ₹345.34 as on 27 Dec 2024, 2.30 'hrs' IST

$4.05

▲

0.08

(2.02%)

Market is closed - opens 8 PM, 27 Dec 2024

View live Nevro share price in Dollar and Rupees. Guide to invest in Nevro from India. Also see the sentimental analysis on Indian investors investing in Nevro. Get details on the Indian mutual funds that are investing in Nevro. Get Analyst recommendations and forecasts along with all the Nevro's financials.

Nevro share price movements

Today's Low: $3.93
Today's High: $4.09
$4.05
2.96%
Downside
Day's Volatility :3.94%
Upside
1.0%
52 Weeks Low: $3.52
52 Weeks High: $22.53
$4.05
13.09%
Downside
52 Weeks Volatility :84.37%
Upside
82.02%

Nevro Returns

Period	Nevro Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	-24.95%	-9.0%	0.0%
6 Months	-52.85%	-4.6%	0.0%
1 Year	-82.03%	3.0%	0.0%
3 Years	-95.29%	0.0%	-21.1%

Nevro Key Statistics

in dollars & INR

Previous Close	$3.97
Open	$3.93
Today's High	$4.0911
Today's Low	$3.93
Market Capitalization	$148.8M
Today's Volume	$235.6K
52 Week High	$22.525
52 Week Low	$3.52
Revenue TTM	$419.1M
EBITDA	$-73.2M
Earnings Per Share (EPS)	$-1.87
Profit Margin	-16.54%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-24.78%

How to invest in Nevro from India?

It is very easy for Indian residents to invest directly in Nevro from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Nevro stock in both Indian Rupees (INR) and US Dollars (USD). Search for Nevro or NVRO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Nevro or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Nevro shares which would translate to 0.211 fractional shares of Nevro as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Nevro, in just a few clicks!

Returns in Nevro for Indian investors in Rupees

Investment Value

₹1,00,000

Nevro investment value today

Current value as on today

₹20,659

Returns

₹79,341

(-79.34%)

Returns from Nevro Stock

₹81,666 (-81.67%)

Dollar Returns

₹2,325 (+2.33%)

Indian investors sentiment towards Nevro

-52%

Period: Sep 27, 2024 to Dec 26, 2024. Change in 30 Days versus previous period

Search volume for Nevro on INDmoney from India has reduced in the last 30 days as on Dec 27, 2024. -52% less investors are searching Nevro in the last 30 days versus the previous period.

Global Institutional Holdings in Nevro

ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
11.72%
Armistice Capital, LLC
9.95%
BlackRock Inc
9.61%
Engaged Capital LLC
6.52%
Vanguard Group Inc
5.59%
BRAIDWELL LP
4.53%

Analyst Recommendation on Nevro

Hold

4%Buy

65%Hold

30%Sell

Based on 23 Wall street analysts offering stock ratings for Nevro(by analysts ranked 0 to 5 stars)

Based on 23 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Nevro

What analysts predicted

Upside of 40.33%

Current:

$4.05

Target:

$5.68

Insights on Nevro

Price Movement
In the last 7 days, NVRO stock has moved up by 10.6%
Decreasing Revenue
Revenue is down for the last 2 quarters, 104.16M → 96.91M (in $), with an average decrease of 7.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -25.40M → -15.34M (in $), with an average increase of 28.7% per quarter
NVRO vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 62.7% return, outperforming this stock by 144.6%
NVRO vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 113.2% return, outperforming this stock by 208.6%
Price to Sales
ForNVRO every $1 of sales, investors are willing to pay $0.3, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Nevro Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$387.3M	↑ 18.56%
Net Income	$-49.2M	↑ 34.23%
Net Profit Margin	-12.7%	↓ 1.48%

	FY19	Y/Y Change
Revenue	$390.3M	↑ 0.77%
Net Income	$-103.7M	↑ 110.72%
Net Profit Margin	-26.57%	↓ 13.87%

	FY20	Y/Y Change
Revenue	$362.0M	↓ 7.23%
Net Income	$-83.1M	↓ 19.89%
Net Profit Margin	-22.94%	↑ 3.63%

	FY21	Y/Y Change
Revenue	$386.9M	↑ 6.87%
Net Income	$-131.4M	↑ 58.14%
Net Profit Margin	-33.95%	↓ 11.01%

	FY22	Y/Y Change
Revenue	$406.4M	↑ 5.03%
Net Income	$3.0M	↓ 102.28%
Net Profit Margin	0.74%	↑ 34.69%

	FY23	Y/Y Change
Revenue	$425.2M	↑ 4.63%
Net Income	$-92.2M	↓ 3172.74%
Net Profit Margin	-21.69%	↓ 22.43%

	Q2 FY23	Q/Q Change
Revenue	$108.8M	↑ 12.96%
Net Income	$-24.7M	↓ 29.42%
Net Profit Margin	-22.72%	↑ 13.64%

	Q3 FY23	Q/Q Change
Revenue	$103.9M	↓ 4.55%
Net Income	$-23.5M	↓ 5.04%
Net Profit Margin	-22.61%	↑ 0.11%

	Q4 FY23	Q/Q Change
Revenue	$116.2M	↑ 11.86%
Net Income	$-9.0M	↓ 61.75%
Net Profit Margin	-7.73%	↑ 14.88%

	Q1 FY24	Q/Q Change
Revenue	$101.9M	↓ 12.29%
Net Income	$-25.4M	↑ 182.92%
Net Profit Margin	-24.94%	↓ 17.21%

	Q2 FY24	Q/Q Change
Revenue	$104.2M	↑ 2.22%
Net Income	$-19.6M	↓ 22.96%
Net Profit Margin	-18.79%	↑ 6.15%

	Q3 FY24	Q/Q Change
Revenue	$96.9M	↓ 6.96%
Net Income	$-15.3M	↓ 21.61%
Net Profit Margin	-15.83%	↑ 2.96%

	FY18	Y/Y Change
Profit	$273.3M	↑ 20.04%

	FY19	Y/Y Change
Profit	$268.4M	↓ 1.82%

	FY20	Y/Y Change
Profit	$249.9M	↓ 6.87%

	FY21	Y/Y Change
Profit	$266.0M	↑ 6.46%

	FY22	Y/Y Change
Profit	$276.4M	↑ 3.88%

	FY23	Y/Y Change
Profit	$290.1M	↑ 4.95%

	Q2 FY23	Q/Q Change
Profit	$74.4M	↑ 15.19%

	Q3 FY23	Q/Q Change
Profit	$69.5M	↓ 6.62%

	Q4 FY23	Q/Q Change
Profit	$78.5M	↑ 12.86%

	Q1 FY24	Q/Q Change
Profit	$67.6M	↓ 13.89%

	Q2 FY24	Q/Q Change
Profit	$67.5M	↓ 0.14%

	Q3 FY24	Q/Q Change
Profit	$64.6M	↓ 4.23%

	FY18	Y/Y Change
Operating Cash Flow	$-5.7M	↓ 60.01%
Investing Cash Flow	$6.4M	↑ 58.1%
Financing Cash Flow	$7.8M	↓ 30.76%

	FY19	Y/Y Change
Operating Cash Flow	$-50.2M	↑ 779.91%
Investing Cash Flow	$32.3M	↑ 402.56%
Financing Cash Flow	$32.1M	↑ 313.89%

	FY20	Y/Y Change
Operating Cash Flow	$1.2M	↓ 102.37%
Investing Cash Flow	$-369.9M	↓ 1244.04%
Financing Cash Flow	$346.9M	↑ 980.94%

	FY21	Y/Y Change
Operating Cash Flow	$-41.9M	↓ 3616.46%
Investing Cash Flow	$201.7M	↓ 154.54%
Financing Cash Flow	$-169.4M	↓ 148.83%

	FY22	Y/Y Change
Operating Cash Flow	$24.7M	↓ 158.92%
Investing Cash Flow	$64.3M	↓ 68.13%
Financing Cash Flow	$-2.5M	↓ 98.55%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-14.5M	↓ 50.53%
Investing Cash Flow	$11.3M	↓ 145.74%
Financing Cash Flow	$4.1M	↓ 281.35%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-6.1M	↓ 58.01%
Investing Cash Flow	$7.3M	↓ 35.4%
Financing Cash Flow	$-1.0M	↓ 124.58%

Nevro Technicals Summary

Sell

Neutral

Buy

Nevro is currently in a neutral trading position according to technical analysis indicators.

Nevro Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Nevro Corp	-13.32%	-52.85%	-82.03%	-95.29%	-96.61%
Stryker Corporation	-4.47%	8.97%	23.96%	36.93%	77.64%
Boston Scientific Corp.	0.35%	18.26%	61.82%	110.62%	102.42%
Edwards Lifesciences Corp.	4.59%	-18.39%	-1.73%	-41.72%	-2.7%
Abbott Laboratories	-3.52%	10.44%	3.95%	-18.3%	32.21%
Medtronic Plc	-5.48%	3.6%	-1.44%	-21.99%	-27.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Nevro Corp	157.5	NA	-3.13	-2.35	-0.25	-0.09	NA	7.31
Stryker Corporation	39.7	39.7	2.56	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	75.26	75.26	1.65	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	29.1	29.1	6.92	2.55	0.19	0.11	NA	16.18
Abbott Laboratories	34.88	34.88	2.22	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	24.94	24.94	1.49	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Nevro Corp	Hold	$148.8M	-96.61%	157.5	-16.54%
Stryker Corporation	Buy	$141.3B	77.64%	39.7	16.34%
Boston Scientific Corp.	Buy	$134.2B	102.42%	75.26	11.26%
Edwards Lifesciences Corp.	Buy	$44.5B	-2.7%	29.1	65.86%
Abbott Laboratories	Buy	$199.0B	32.21%	34.88	13.99%
Medtronic Plc	Buy	$104.6B	-27.8%	24.94	12.06%

About Nevro

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.

Organization	Nevro
Employees	1215
CEO	Mr. Kevin R. Thornal
Industry	Health Technology

Management People of Nevro

Name	Title
Mr. Kevin R. Thornal	President, CEO & Director
Mr. Roderick H. MacLeod	Senior VP & CFO
Mr. Kashif Rashid J.D.	Senior VP of Corporate Development & Chief Legal Officer
Mr. Greg Siller	Senior VP & Chief Commercial Officer
Mr. Christofer Christoforou	Senior VP & COO
Ms. Angeline C. McCabe	Vice President of Investor Relations & Corporate Communications
Ms. Shana D. Ross M.B.A.	Senior VP & Chief Human Resources Officer
Dr. David Caraway M.D., Ph.D.	Senior VP & Chief Medical Officer
Mr. Peter A. Socarras	VP, General Counsel & Corporate Secretary

Important FAQs about investing in Nevro from India :

What is Nevro share price today?

Nevro share price today stands at $4.05, Open: $3.93 ; Previous Close: $3.97 ; High: $4.09 ; Low: $3.93 ; 52 Week High: $22.53 ; 52 Week Low: $3.52. The stock opens at $3.93, after a previous close of $3.97. The stock reached a daily high of $4.09 and a low of $3.93, with a 52-week high of $22.53 and a 52-week low of $3.52.

Can Indians buy Nevro shares?

Yes, Indians can invest in the Nevro (NVRO) from India.

With INDmoney, you can buy Nevro at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Nevro at zero transaction cost.

How can I buy Nevro shares from India?

It is very easy to buy Nevro from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Nevro be purchased?

Yes, you can buy fractional shares of Nevro with INDmoney app.

What are the documents required to start investing in Nevro stocks?

To start investing in Nevro, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.